Breast Cancer

Articles

The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab.

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

Videos

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

Relapsed/Refractory HER2+ Metastatic Breast Cancer

Results from the phase 3 SOPHIA trial demonstrated that margetuximab plus chemotherapy had an acceptable safety profile which was comparable to that observed with trastuzumab plus chemotherapy.

Margetuximab Plus Chemo Improves PFS Versus Trastuzumab/Chemo in ERBB2+ Advanced Breast Cancer

The randomized, open-label, phase 3 FeDeriCa trial tested the safety profile of pertuzumab and trastuzumab plus hyaluronidase-zzxf in 500 patients with HER2-positive early breast cancer.

Subcutaneous Pertuzumab and Trastuzumab Combo for HER2-Positive Early Breast Cancer Shown as Noninferior to Intravenous Infusions

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.

Around the Practice: January 2021 Virtual Tumor Board

ARX788 received a nod from the FDA early in 2021 based on promising preclinical and phase 1 trial data demonstrating its efficacy in patients with HER2-positive breast cancer following progression on other agents. 

FDA Action Moves ARX788 Forward in the Treatment of HER2-Positive Breast Cancer

The FDA approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease.

FDA Approves Margetuximab-cmkb, Chemo Combo for Pretreated Metastatic HER2+ Breast Cancer

Impressive signals of efficacy, durable responses, overall survival rates, and a tolerable safety profile were all found for fam-trastuzumab deruxtecan-nxki to treat patients with HER2-positive metastatic breast cancer.

Impressive Efficacy Reported for Trastuzumab Deruxtecan to Treat HER2+ Metastatic Breast Cancer

The combination use of neoadjuvant paclitaxel, trastuzumab, and pertuzumab followed by adjuvant trastuzumab for patients with pathologic complete response or followed by adjuvant dose-dense anthracycline/cyclophosphamide plus T-DM1 for patients with residual disease offered the highest health benefits and lowest costs.

Study Identifies Cost-Effective Strategies for Neoadjuvant-Adjuvant Treatment of HER2-Positive Breast Cancer

Investigators suggested that guidelines which recommend initiating screening mammography at age 50 may be putting Black women at a disadvantage, and screening should thus begin by age 40.

HER2-Positive Breast Cancer | Topics